SLC5A2 and heart failure: The results from ongoing trial examining dapagliflozin (Dapagliflozin Effect on CardiovascuLAR Events [40]) remain crucial for establishing the class-level effect of SGLT2 inhibitors on risk of heart failure hospitalization, although a recent meta-analysis suggests that the effect of dapagliflozin on heart failure hospitalization is comparable to empagliflozin [41].